Current Controversies in the Management of Myeloma Bone Disease

Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti‐myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone‐targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti‐myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti‐resorptive therapy, risks and benefits of long term anti‐resorptive therapy, and whether anti‐resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. J. Cell. Physiol. 231: 2374–2379, 2016. © 2016 Wiley Periodicals, Inc.